Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468866 | 0.95 | MET (0.43) | METTSHRALDH1A1L3MBTL1MEN1 | |
| SCHEMBL2466209 | 0.94 | MET (0.46) | METTSHRALDH1A1L3MBTL1USP2 | |
| SCHEMBL2469433 | 0.93 | MET (0.44) | METTSHRALDH1A1L3MBTL1USP2 | |
| SCHEMBL1953412 | 0.93 | MET (0.53) | MET | |
| SCHEMBL2466179 | 0.91 | MET (0.56) | METTSHRALDH1A1L3MBTL1USP2 | |
| SCHEMBL2472186 | 0.90 | MET (0.52) | MET | |
| Formic Acid SCHEMBL1949906 | 0.88 | MET (0.37) | METTSHRALDH1A1L3MBTL1 | |
| SCHEMBL2466028 | 0.88 | MET (0.45) | METTSHRALDH1A1L3MBTL1USP2 | |
| SCHEMBL2472162 | 0.88 | MET (0.52) | METTSHRALDH1A1L3MBTL1MEN1 | |
| SCHEMBL2468137 | 0.87 | MET (0.53) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960370-B1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2011-10-05 | — | — | EP | claimed |
| US-20110136819-A1 | 6-THIOXOPYRIDAZINE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136819-A1 | 6-THIOXOPYRIDAZINE DERIVATIVES | RET, ABL1, JAK2 | MET 4/4885TSHR 173/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.